| Symbol | TARA |
|---|---|
| Name | PROTARA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 345 PARK AVENUE SOUTH,3RD FLOOR, NEW YORK, New York, 10010, United States |
| Telephone | +1 646 844-0337 |
| Fax | — |
| — | |
| Website | https://www.protaratx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001359931 |
| Description | Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD). Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Protara Therapeutics, Inc. <b>Filed:</b> 2026-07-07 <b>AccNo:</b> 0001104659-26-081389 <b>Size:</b> 18 KB
Read more(99% Neutral) PROTARA THERAPEUTICS, INC. (TARA) Announces New Board Appointment
Read more📋 JESSE SHEFFERMAN (Officer) plans to sell 216K shares of PROTARA THERAPEUTICS, INC. (at $4.09 each, total $882K) Filed: Jun 29, 2026 | ID: 006626
Read moreLevy Richard S 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069250
Read moreSolomon Michael Edward 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069249
Read moreSmith Cynthia 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069248
Read moreSARGEN GREGORY 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069247
Read moreHuang Jane 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069246
Read moreGARCEAU ROGER 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069245
Read moreFlannelly Barry P 🟢 acquired 31.0K shares (1 derivative) of Protara Therapeutics, Inc. (TARA) at $3.94 Transaction Date: Jun 15, 2026 | Filing ID: 069244
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07480356 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choic… | Phase3 | Bladder (Urothelial, Transitional Cell) Cancer | Recruiting | 2026-05-29 | 2032-11-01 | ClinicalTrials.gov |
| NCT06910943 | Study of Choline Chloride for Injection in Adolescent and Adult Patients With I… | Phase2 | Choline Deficiency | Recruiting | 2025-12-10 | 2028-06-01 | ClinicalTrials.gov |
| NCT05871970 | Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphati… | Phase2 | Lymphatic Malformation | Recruiting | 2023-10-18 | 2027-05-01 | ClinicalTrials.gov |
| NCT05951179 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults Wi… | Phase2 | Non-muscle Invasive Bladder Cancer | Recruiting | 2023-09-15 | 2032-03-01 | ClinicalTrials.gov |
| NCT05085990 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults wi… | Phase1 | Non-muscle Invasive Bladder Cancer | Completed | 2023-05-08 | 2024-09-12 | ClinicalTrials.gov |
| NCT05085977 | Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults wi… | Phase1 | Non-muscle Invasive Bladder Cancer | Completed | 2022-03-10 | 2024-10-30 | ClinicalTrials.gov |
| NCT05011370 | Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition | — | Intestinal Failure-associated Liver Disease | Completed | 2021-08-23 | 2023-06-29 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| Investigator's Choice of Intravesical Chemotherapy | Drug | Phase PHASE3 | Bladder (Urothelial, Transitional Cell) Cancer | RECRUITING | NCT07480356 |
| TARA-002 | Other | Phase PHASE3 | Bladder (Urothelial, Transitional Cell) Cancer | RECRUITING | NCT07480356 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| TARA-002 | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05085990 |
| TARA-002 | Other | Phase PHASE1 | Non-muscle Invasive Bladder Cancer | COMPLETED | NCT05085977 |
| TARA-002 | Other | Phase PHASE2 | Lymphatic Malformation | RECRUITING | NCT05871970 |
| Placebo | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| Choline Chloride for Injection | Other | Phase PHASE2 | Choline Deficiency | RECRUITING | NCT06910943 |
| TARA-002 | Other | Phase PHASE2 | Non-muscle Invasive Bladder Cancer | RECRUITING | NCT05951179 |